Boris Johnson praised two arthritis drugs that researchers claim to be very effective in severe COVID-19 patients. They also stated that new medicines could reduce death cases by up to 24%.
Bloomberg reported that the United Kingdom confirmed that it would start using Roche Holding AG arthritis drug to cure COVID-19 patients that are suffering from extreme symptoms.
On the other hand, the country's prime minister confirmed that the anti-inflammatory drugs sarilumab and tocilizumab would be available through the NHS.
When will the arthritis be available?
The scientists claimed that the two drugs would have an immediate effect and could save thousands of lives once they are implemented.
"I'm pleased to tell you today British scientific research has now contributed to the creation of more new life-saving treatments that have just passed rigorous clinical trials," said Johnson via The Daily Mail UK.
He added that the two drugs would soon be available to everyone since the researchers found out they can decrease the time spent in intensive care by as much as ten days.The prime minister also said that medicines could reduce critical ill patients' death risks.
"These life-saving drugs will be available through the NHS with immediate effect, potentially saving thousands of lives," he added.
On the other hand, the researchers also discovered that the two new drugs are useful for patients who are taking dexamethasone. This medicine is a steroid that the British scientists discovered to reduce the most severe COVID-19 patients' death risks over summer.
Can the new study shed light during the COVID-19 pandemic?
The British politician Matt Hancock said that the new study is another breakthrough during the ongoing global pandemic. The discovery could really be helpful, especially since there are new strains of the novel coronavirus that are now spreading across many countries, including Singapore, China, and more.
REMAP-CAP trial is the one that released the new study's results, which involved 3,900 people with severe COVID-19 symptoms in 15 countries. The drugs will be marketed under the brand names Kevzara and Actemra. They are expected to be administered via an intravenous drip for an hour.
The new study revealed that those who took the two new drugs dropped their death rate by 25.3%. On the other hand, the patients who only received dexamethasone had a death rate of 35.8%.
For more news updates about new COVID-19 drugs, always keep your tabs open here at TechTimes.
Related Article: UK and US Requires Their Residents to Take Two COVID-19 Vaccine Jabs! How Fast Would You Need the 2nd One?
This article is owned by TechTimes.
Written by: Giuliano de Leon.
